14770-79-7

Usage

Uses

Used in Pharmaceutical Research:
Benzo[b]thiophen-2-amine, 4,5,6,7-tetrahydro(8CI,9CI) is used as a building block in the synthesis of other organic compounds for pharmaceutical research. Its unique structure and properties make it a valuable component in the development of new drugs or materials.
Used in Organic Chemistry:
In the field of organic chemistry, Benzo[b]thiophen-2-amine, 4,5,6,7-tetrahydro(8CI,9CI) is utilized for its potential applications in the synthesis and study of heterocyclic amines and related compounds, contributing to the advancement of chemical knowledge and innovation.
Used in Drug Development:
Benzo[b]thiophen-2-amine, 4,5,6,7-tetrahydro(8CI,9CI) may be employed in the development of new drugs, leveraging its chemical properties to create novel therapeutic agents that address various medical conditions. Its potential applications in drug development highlight its importance in the pharmaceutical industry.

InChI:InChI=1/C8H7NS/c9-8-5-6-3-1-2-4-7(6)10-8/h1-5H,9H2

Upstream product

• 5936-58-3 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid 
• 108-94-1 cyclohexanone 
• 4506-71-2 ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 120004-49-1 [1-(3-Nitro-phenyl)-meth-(E)-ylidene]-(4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-amine 
• 106970-93-8 2-Methyl-4-(3-nitro-phenyl)-1,4,5,6,7,8-hexahydro-benzo[4,5]thieno[2,3-b]pyridine-3-carboxylic acid methyl ester 
• 14346-24-8 5,6,7,8-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyrimidin-4-one 
• 40493-18-3 4-chloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine 

Relevant academic research and scientific papers

Thiophene/thiazole-benzene replacement on guanidine derivatives targeting α2-Adrenoceptors

Searching for improved antagonists of α2-adrenoceptors, a thorough theoretical study comparing the aromaticity of phenyl-, pyridinyl-, thiophenyl- and thiazolylguanidinium derivatives has been carried out [at M06-2X/6–311++G(p,d) computational level] confirming that thiophene and thiazole will be good ‘ring equivalents’ to benzene in these guanidinium systems. Based on these results, a small but chemically diverse library of guanidine derivatives (15 thiophenes and 2 thiazoles) were synthesised to explore the effect that the bioisosteric change has on affinity and activity at α2-adrenoceptors in comparison with our previously studied phenyl derivatives. All compounds were tested for their α2-adrenoceptor affinity and unsubstituted guanidinothiophenes displayed the strongest affinities in the same range as the phenyl analogues. In the case of cycloakyl systems, thiophenes with 6-membered rings showed the largest affinities, while for the thiazoles the 5-membered analogue presented the strongest affinity. From all the compounds tested for noradrenergic activity, only one compound exhibited agonistic activity, while two compounds showed very promising antagonism of α2-adrenoceptors.

Discovery of novel akt1 inhibitor induces autophagy associated death in hepatocellular carcinoma cells

In this study, a series of thieno [2,3-d]pyrimidine derivatives were designed, synthesized and evaluated as novel AKT1 inhibitors. In vitro antitumor assay results showed that compounds 9d-g and 9i potently suppressed the enzymatic activities of AKT1 and

NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, E and n are as described herein, compositions including the compounds and use thereof as fatty-acid binding protein (FABP) 4/5 inhibitors in the treatment of e.g. type 2 diabetes, atherosclerosis or cancer.